Oncoinvent Solutions

Oncoinvent is a clinical-stage radiopharmaceutical company based in Oslo, Norway, focused on developing innovative alpha-emitting therapies for the treatment of solid cancers. The company's lead product candidate, Radspherin, is a radium-224 based microparticle suspension designed to treat metastatic cancers in body cavities, with a primary focus on peritoneal carcinomatosis from ovarian and colorectal cancers. Founded by the pioneers behind the first FDA-approved alpha therapy, Xofigo, Oncoinvent utilizes a proprietary technology platform to deliver high-power radiation directly to tumor sites while minimizing systemic side effects. The company operates its own GMP-certified manufacturing facility to support its clinical programs and is currently advancing Radspherin through Phase 2 clinical trials. Following a strategic merger with BerGenBio in 2025, Oncoinvent is publicly traded on the Euronext Oslo Børs under the ticker ONCIN.